Trial Finds a Common Blood Pressure Drug Helped More Stroke Survivors Reach Their Target, With Some Added Risk
A randomized trial called REDUCE tested spironolactone, an inexpensive blood pressure drug, in stroke survivors. In the trial, 52% of patients taking the drug reached the secondary-prevention target of below 130/80, compared with 30% of patients on usual care. Home systolic pressure fell by nearly eight points more with the drug. High potassium, called hyperkalemia, occurred in 4% of patients on the drug and none on usual care, with no life-threatening complications reported. The trial enrolled 160 people, was open-label, and ended early. The results were presented at a cardiology meeting and are preliminary.
Blood pressure control is one of the most effective ways to prevent a second stroke, yet many survivors stay above target. A low-cost drug that closes part of that gap is notable, but a small early-stopped trial cannot settle safety, especially for patients with kidney problems.
If you or a relative has had a stroke, do not start or change medication on the strength of one small trial. Ask a doctor about your blood pressure target and whether this drug is appropriate given your kidney function and potassium levels.
Researchers who favor the drug say the gain in reaching the target is large for a cheap, widely available medicine, and the exploratory results suggest starting it soon after the stroke may help more.
Others caution that the trial was small, open-label and stopped early, that patients with weak kidney function were excluded, and that hyperkalemia can be dangerous outside a closely watched study.
Confirmed: the reported results of the REDUCE trial and the higher rate of hyperkalemia. Not confirmed: whether larger, blinded trials will find the same benefit, or how safe the drug is for patients with kidney disease. Watch for peer-reviewed publication.
DailyDrop U.S. No. 43 · November 16, 2026